01
Proprietary Platform
We develop AI-designed biomaterials through our plant and protein-agnostic platform, PCT pending, combined with optimised plant-based production systems ensuring high biocompatibility at significantly lower costs.
Technology & Moat
Our advantage
A defensible, vertically integrated stack - from AI-designed molecules to PCT-pending expression systems and plant-based production at scale.
02
Data-Driven Optimisation
Each production cycle improves future design through integrated data feedback.
03
Scalable Infrastructure
Our plant-based systems reduce reliance on expensive fermentation infrastructure and its lack of versatility due to optimisation requirements for each batch. Our proprietary expression systems enable 5x yield gains at high protein stability.
04
IP Strategy
Our PCT-pending proprietary expression systems, design workflows, and platform innovations sit at the core of our IP.
5x
Yield gains via proprietary expression systems
PCT
Pending across expression systems and workflows
∞
Plant & protein-agnostic by design